1. Home
  2. ANL vs ORRF Comparison

ANL vs ORRF Comparison

Compare ANL & ORRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.20

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Logo Orrstown Financial Services Inc

ORRF

Orrstown Financial Services Inc

HOLD

Current Price

$39.19

Market Cap

699.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANL
ORRF
Founded
2004
1919
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
731.6M
699.5M
IPO Year
2022
1995

Fundamental Metrics

Financial Performance
Metric
ANL
ORRF
Price
$10.20
$39.19
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$20.00
$42.00
AVG Volume (30 Days)
129.2K
83.6K
Earning Date
04-10-2026
04-21-2026
Dividend Yield
N/A
3.29%
EPS Growth
N/A
182.43
EPS
N/A
1.12
Revenue
N/A
$37,144,000.00
Revenue This Year
$36.02
N/A
Revenue Next Year
N/A
$3.15
P/E Ratio
N/A
$34.79
Revenue Growth
N/A
36.00
52 Week Low
$0.88
$29.40
52 Week High
$17.25
$40.72

Technical Indicators

Market Signals
Indicator
ANL
ORRF
Relative Strength Index (RSI) 40.94 65.06
Support Level $6.92 $34.95
Resistance Level $12.59 $40.22
Average True Range (ATR) 1.15 1.12
MACD -0.11 0.26
Stochastic Oscillator 26.07 93.58

Price Performance

Historical Comparison
ANL
ORRF

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About ORRF Orrstown Financial Services Inc

Orrstown Financial Services Inc is a financial holding company. Through its subsidiaries, it operates in the community banking segment and engages in lending activities, including commercial, residential, commercial mortgages, construction, municipal, and various forms of consumer lending and deposit services, including checking, savings, time, and money market deposits. The Group also provides fiduciary, investment advisory, insurance, and brokerage services. It offers services to individuals, professionals, small businesses, and other enterprises across different locations in the United States through its branch network and client service centers.

Share on Social Networks: